【Apricot Blossom】Announcement by the Company in Accordance with Article 25, Paragraph 1, Subparagraph 4 of the Regulations Governing Loans of Funds and Endorsement Guarantees by Public Companies

1. Date of occurrence of the event: 2026/05/05 2. Company for which endorsement guarantee was provided: (1) Company name: Apricot Blossom Biotech Co., Ltd. (2) Relationship with the company providing endorsement guarantee: This company is a subsidiary in which the company directly holds 64.26% of the voting shares. (3) Endorsement guarantee limit (in thousands of NTD): 1,414,886 (4) Original endorsement guarantee balance (in thousands of NTD): 0 (5) Amount of new endorsement guarantee provided this time (in thousands of NTD): 200,000 (6) Endorsement guarantee balance as of the date of occurrence (in thousands of NTD): 200,000 (7) Actual amount utilized by the company receiving endorsement guarantee (in thousands of NTD): 0 (8) Reason for new endorsement guarantee this time: Renewal of the expired bank credit line for which an endorsement guarantee had been previously provided to a subsidiary. 3. Collateral provided by the company receiving endorsement guarantee: (1) Content: None (2) Value (in thousands of NTD): 0 4. Recent financial statements of the company receiving endorsement guarantee: (1) Capital (in thousands of NTD): 351,645 (2) Accumulated profit/loss (in thousands of NTD): -95,290 5. Conditions for release of endorsement guarantee liability: (1) Conditions: Release upon repayment at the expiration of the contract. (2) Date: Upon expiration of the contract term or repayment at the expiration of the contract. 6. Total endorsement guarantee limit (in thousands of NTD): 1,768,608 7. Endorsement guarantee balance as of the date of occurrence (in thousands of NTD): 230,000 8. Ratio of endorsement guarantee balance provided by A as of the date of occurrence to the net worth of the public company's most recent financial statements: 6.50% 9. Ratio of the total sum of endorsement guarantee, long-term investments, and loans of funds balance as of the date of occurrence to the net worth of the public company's most recent financial statements: 41.75% 10. Other matters that should be specified: None